REVIEW_FUTURE_ONCOLOGY._IRIS_EU9_Suppl_Tables_TC_v2.0_06.09.21.docx (98.65 kB)
Download file

Supplementary Tables – Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study

Download (98.65 kB)
dataset
posted on 29.11.2021, 15:17 by Figshare Future Science GroupFigshare Future Science Group, Katie Mycock, Lin Zhan, Kieran Hart, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra

Supplementary Table S1. Patient inclusion criteria

Supplementary Table S2. Therapeutic indications for IBRANCE (palbociclib) in the EU

Supplementary Table S3. Patient demographics and clinical characteristics for the nine individual EU countries

Supplementary Table S4. Palbociclib treatment patterns for the nine individual EU countries

Supplementary Table S5. Response to palbociclib treatment for the nine individual EU countries

Real-world treatment of patients with palbociclib for HR+/HER2– advanced/metastatic breast cancer: the Europe IRIS study

Funding

Pfizer

History